Collectively, these findings advance the pharmacological landscape of GLP-1 and its derived peptides, suggesting that they are versatile agents for comprehensive treatment strategies for chronic pain syndromes linked with metabolic disorders. The gene discussed is GCG; the disease is Other metabolic disease.